Future COVID-19 Tests Could Be Based on Biomarkers and Molecular Profiles of Individuals

People have different susceptibilities to the SARS-CoV-2 virus and develop varying degrees of fever, fatigue, and breathing problems - common symptoms of the illness. Scientists at the University of California, Riverside (Riverside, CA, USA) and University of Southern California (Los Angeles, CA, USA) may have an answer to explain this variation. The scientists have shown for the first time that the observed COVID-19 variability may have underlying molecular sources. The finding could help in the development of effective prophylactic and therapeutic strategies against the disease.

The SARS-CoV-2 virus hijacks human host molecules for fusion and virus replication, attacking human cellular functions. These human host molecules are collectively called SARS-CoV-2 host genes. The scientists systematically analyzed SARS-CoV-2 host gene expression, their variations, and age- and sex-dependency in the human population using large-scale genomics, transcriptomics, and proteomics. They first found similarity of host gene expression is generally correlated with tissue vulnerability to SARS-CoV-2 infection. Among the six most variably expressed genes in the population they identified ACE2, CLEC4G, and CLEC4M, which are known to interact with the spike protein of SARS-CoV-2.

Higher expression of these genes likely increases the possibility of being infected and of developing severe symptoms. Other variable genes include SLC27A2 and PKP2, both known to inhibit virus replication; and PTGS2, which mediates fever response. The scientists also identified genetic variants linked to variable expression of these genes. According to them, the expression profiles of these marker genes may help better categorize risk groups. In addition to identifying the most variable SARS-CoV-2 host genes, results from the study suggest genetic and multiple biological factors underlie the population variation in SARS-CoV-2 infection and symptom severity. Next, the researchers plan to further analyze large scale genotypes and transcriptome data of COVID-19 patients when made available and to refine the results for higher association and accuracy.

“Based on biomarkers and molecular profiles of individuals, one would hope to develop better medical tests to accommodate these variations in monitoring virus transmission and disease pathology, which helps guide mitigation and treatment options,” said Sika Zheng, an associate professor of biomedical sciences at the UC Riverside School of Medicine, who led the study.

“More comprehensive risk assessment can better guide the early stage of vaccine distribution,” added Zheng. “Tests can also be developed to include these molecular markers to better monitor disease progression. They can also be used to stratify patients to assess and ultimately enhance treatment effectiveness.”

Related Links:
University of California